With regard to Martin Blaser's concerns about the collateral damage to commensal bacteria caused by overuse of broad-spectrum antibiotics (Nature 476, 393–394; 2011), there are some potent alternatives in the pipeline.
Bacteriocins are peptide antimicrobials that could be harnessed to control a variety of problematic pathogens. Many bacteriocins act only on a narrow range of targets and are active at very low (nanomolar) concentrations. For example, we found that thuricin CD specifically eliminates Clostridium difficile bacteria from among the trillions of bacteria in a model gut system (M. C. Rea et al. Proc. Natl Acad. Sci. USA 108, S4639–S4644; 2011). Diarrhoea associated with C. difficile infection is an often-fatal disease resulting from the growth of antibiotic-resistant spores after disruption of the gut microbiota by antibiotics.
Researchers are beginning to identify microbes and human microbial populations that are associated with conditions as wide-ranging as liver, coeliac and inflammatory bowel diseases, obesity, diabetes, irritable bowel syndrome, colon cancer, pouchitis and even mental health. We believe that bacteriocins could be used in the future to design and shape 'healthy' bacterial communities.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
P.C. and R.P.R. work for Teagasc, a national, government-funded research body. All three authors are investigators within the Alimentary Pharmabiotics Centre, which works on new gastrointestinal therapies (including bacteriocins), with input from other biotechnology companies.
Rights and permissions
About this article
Cite this article
Cotter, P., Ross, R. & Hill, C. Flagging flora: help from bacteriocins?. Nature 477, 162 (2011). https://doi.org/10.1038/477162c
Published:
Issue Date:
DOI: https://doi.org/10.1038/477162c